Pfizer's Q4 revenue beats expectations with ... it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.

(Reuters) -Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Pfizer expressed confidence in sustaining growth across oncology, cardiovascular, and vaccines, backed by strong commercial execution and market share gains. Pfizer reported Q4 2024 revenue of $17 ...

Pfizer already makes big revenues ... iDFS than hormone therapy alone in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early-stage breast cancer.

Pfizer Inc (NYSE:PFE) successfully integrated the Seagen business, enhancing its oncology capabilities. The company achieved strong financial performance with a 12% operational revenue growth ...

Pfizer's future growth hinges on successful R&D and commercialization of new drugs, particularly in oncology, amidst a challenging pharmaceutical landscape. At issue was Pfizer's guidance ...

Analyst firm Edward Jones expects Pfizer’s future growth to accelerate. Net income was $410 million, or 7 cents a share, after a loss of $3.37 billion, or 60 cents a share, in the prior year’s ...